Business Context and Reporting Period
Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: BioCryst is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs. Key programs include peramivir (an influenza neuraminidase inhibitor) and forodesine (a PNP inhibitor for oncology and autoimmune diseases). The company relies heavily on government contracts (HHS) and strategic collaborations for funding and revenue.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2009 | Nine Months Ended Sept 30, 2009 | Balance Sheet (Sept 30, 2009) |
|---|---|---|---|
| Revenues | $10,548 | $19,694 | - |
| Net Loss | $(10,627) | $(28,603) | - |
| Loss Per Share (Basic/Diluted) | $(0.28) | $(0.75) | - |
| Cash and Cash Equivalents | - | - | $18,226 |
| Marketable Securities | - | - | $20,266 |
| Total Assets | - | - | $60,588 |
| Total Liabilities | - | - | $37,043 |
| Stockholders' Equity | - | - | $23,545 |
Liquidity: As of September 30, 2009, the company held approximately $38.5 million in cash, cash equivalents, and marketable securities. The company reported a net cash burn rate of approximately $2.8 million per month in 2009.
Material Changes vs. Prior Period
- Revenue:
- Three Months: Increased 18.6% to $10.5 million from $8.9 million in Q3 2008, driven by higher HHS contract revenue and Shionogi collaboration revenue, partially offset by lower Mundipharma revenue.
- Nine Months: Decreased 11.8% to $19.7 million from $22.3 million in the prior year, primarily due to reduced Mundipharma revenue and lower amortization of deferred revenue, despite higher HHS revenue.
- Expenses:
- R&D Expenses: Increased 13.7% for the quarter ($18.2M vs $16.0M) due to higher manufacturing costs for peramivir. For the nine months, R&D expenses decreased 20.6% ($40.7M vs $51.3M) due to reduced clinical and toxicology costs.
- G&A Expenses: Increased 24.0% for the quarter ($3.1M vs $2.5M) due to legal and consulting fees. For the nine months, G&A decreased slightly ($7.8M vs $8.0M).
- Net Loss:
- Three Months: Net loss widened to $10.6 million from $9.0 million.
- Nine Months: Net loss narrowed to $28.6 million from $34.8 million, reflecting significant cost reductions in R&D.
- Interest Income: Significantly decreased in both periods due to lower average cash balances and reduced yields on interest-bearing assets.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Peramivir (Influenza):
- Initiated two Phase 3 studies for i.v. peramivir in hospitalized patients (target enrollment ~700).
- Received a $77.2 million contract modification from HHS, bringing total funding to $179.9 million and extending the term to five years.
- Received an initial order for 10,000 courses of i.v. peramivir valued at $22.5 million from HHS in November 2009 (subsequent event).
- Shionogi filed an NDA in Japan for i.v. peramivir, triggering a $7.0 million milestone payment (subsequent event).
- Discontinued development of the intramuscular (i.m.) formulation following non-statistically significant Phase 2 results.
- Forodesine (Oncology):
- Continuing pivotal Phase 2 trial for Cutaneous T-Cell Lymphoma (CTCL); preliminary data expected in H1 2010.
- Initiated a Phase 2 trial for Chronic Lymphocytic Leukemia (CLL); interim data showed no complete responses but substantial reductions in malignant lymphocytes in some patients.
- Cash Needs: Management expects cash use for 2009 to be near the top end of the previous guidance range ($30–$38 million). Resources are deemed sufficient to fund operations for at least the next 12 months, contingent on HHS and partner funding.
Risks and Contingencies
- HHS Contract Risk: Revenue projections are heavily dependent on HHS reimbursement. The contract is subject to audit, modification, or termination by the government without cause. A $4.9 million reserve was recorded in 2008 for uncertain HHS costs related to the terminated i.m. peramivir program; discussions are ongoing regarding recovery.
- Dispute with Mundipharma: The company is in dispute with Mundipharma regarding contractual obligations for forodesine development costs. Potential exposure is estimated at $2.5 million; no accrual has been made as of September 30, 2009.
- Capital Requirements: The company has incurred losses since inception and expects to continue doing so. Additional capital will be required to complete development and commercialization, which may not be available on acceptable terms.
- Regulatory and Clinical Risks: Clinical trials may fail to demonstrate safety or efficacy. Regulatory approval is not guaranteed, and delays could significantly impact cash flow and business viability.
Investor Verification Checklist
- HHS Contract Status: Verify the status of the $77.2 million contract modification and the resolution of the $5.0 million excess API repurchase tender.
- Subsequent Events: Confirm the receipt of the $22.5 million HHS order and the $7.0 million Shionogi milestone payment announced in November 2009.
- Mundipharma Dispute: Monitor the resolution of the $2.5 million cost dispute and any potential impact on future revenue recognition.
- Cash Burn Rate: Assess the sustainability of the ~$2.8 million monthly burn rate against current cash reserves ($38.5M) and expected HHS inflows.
- Clinical Trial Progress: Track enrollment and interim data for the i.v. peramivir Phase 3 trials and the forodesine CTCL/CLL trials.